Yaowei Zhu - Concepedia

Concepedia

Author

Yaowei Zhu

Janssen (United States)ORCID

Also Known As

Y -W. Zhu, Y W Zhu, Y. Zhu, Y.W. Zhu, Yaowei Zhu

26

Publications

1.4K

Citations

16

H-Index

21

Concepts

All Affiliations

Janssen (United States)University of California San Diego Dalhousie University Universität Hamburg Springhouse

YZ

About

Yaowei Zhu is an author at Janssen (United States) specializing in medicine, dermatology, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	724
2	Immunology	3	3	500
3	Health Sciences	1	1	77
4	Clinical Immunology	1	1	275
5	Epidemiology	1	1	59

Yaowei Zhu

×

17

Publications

1.4K

Citations

14

H-Index

	Year	Citations
A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis Catharine Lisa Kauffman, Nancy Aria, Eiko Toichi, Journal of Investigative Dermatology Clinical ImmunologyMedicineImmunologyInflammatory MarkerPlaque Psoriasis	2004	275
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study Ian Landells, Colleen Marano, Ming-Chun Hsu, Journal of the American Academy of Dermatology	2015	220
Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis Yaowei Zhu, Chuanpu Hu, Ming Lu, The Journal of Clinical Pharmacology Rheumatoid DisorderAutoimmune DiseaseMedicineSevere Plaque PsoriasisImmunology	2009	166
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations Mark Lebwohl, Newman Yeilding, Philippe Szapary, Journal of the American Academy of Dermatology MedicineSevere PsoriasisClinical DermatologyPharmacotherapyDermatology	2010	128
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial Arthur Kavanaugh, L. Puig, Alice B. Gottlieb, Arthritis Care & Research	2015	105
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis Alice B. Gottlieb, Kevin D. Cooper, Thomas S. McCormick, Current Medical Research and Opinion	2007	104
Human liver microsomal metabolism of paclitaxel and drug interactions Pankaj B. Desai, John Duan, Yaowei Zhu, European Journal of Drug Metabolism and Pharmacokinetics MedicineLiver PhysiologyHepatotoxicityMicrosomal MetabolismMetabolomics	1998	77
Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label <scp>CADMUS</scp> Jr study Sandra Philipp, Alan Menter, Arjen Nikkels, British Journal of Dermatology	2020	77
Population‐Based Exposure‐Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis Honghui Zhou, Chuanpu Hu, Yaowei Zhu, The Journal of Clinical Pharmacology Exposure‐efficacy ModelingSevere Plaque PsoriasisImmunologyDermatologyPsoriatic Arthritis	2009	59
Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance Kristian Reich, Kenneth B. Gordon, Bruce Strober, Journal of the European Academy of Dermatology and Venereology	2022	30

Page 1